Since the beginning of the company’s transformational journey in 2016 we have tripled our client base and today a wide range of mostly international companies –…
In Conversation
The ambitious mindset that the Saudi Arabia Vision 2030 sets out fits well with the mentality we are embracing at Novartis. I like to say that…
[R&D] is the gateway to successful production and competition in the marketplace. Without R&D, DEVA would not be where it is today
We want to be the prime example of an innovative, science-driven biotech from China, showcasing the best of world capability in terms of innovation, rather than…
General attitudes towards the pharmaceutical industry have shifted, with an increasing realization of the importance of local research and production and an obligation in some geographies…
The pandemic has forced every industry to rethink its operating model. For us in pharma, COVID-19 really sped up the adoption of digitalisation
Switzerland generally offers attractive conditions and a stable environment for international companies. The country offers an environment favourable to innovation, a good infrastructure, a highly skilled…
Cellestia has established itself as one of the leading companies in the discovery, research and development of innovative, first-in-class therapeutics targeting gene transcription factors for the…
In general, biotech and life science companies [that list in Switzerland] benefit from a strong peer group and are helped by the fact that the listing…
Zurich was a good fit for EraCal’s novel platform idea. There is more room for error here and the Swiss ecosystem truly has fantastic initiatives to…
Bristol Myers Squibb has lent its full support to Saudi Arabia’s 2030 Strategic Vision, and we are happy to see that the pharma industry has been…
As a result of Turkey’s high-quality medical treatment, medical tourism is significantly increasing. Patients from all around the world, especially the Middle East, are coming to…
